Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement. application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

| Name of entity |
|---|
| CYNATA THERAPEUTICS LIMITED |
| ABN |
| 98 104 037 372 |
| Ma (the continue of the ACV the fellowing information |
| We (the entity) give ASX the following information. |
| Part 1 - All issues |
| You must complete the relevant sections (attach sheets if there is not enough space). |
| |

issued 2 Number of +securities issued or to be issued (if known) or maximum

+Class of +securities issued or to be

1

Unlisted Options

number which may be issued

400,000 Adviser Options

3 Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if securities, +convertible the conversion price and dates for conversion)

Adviser Options - exercisable at \$0.40 each, expiring 30 November 2015, vesting on 1 December 2014

⁺ See chapter 19 for defined terms.

Shares issued upon exercise of the Unlisted 4 Do the +securities rank equally in Options will rank equally in all respects from the all respects from the date of date of issue with the existing quoted Ordinary allotment with an existing +class of Fully Paid Shares of the Company. quoted *securities? If the additional securities do not rank equally, please state: the date from which they do the extent to which they for the participate next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 5 Issue price or consideration Nil 6 Purpose of the issue Issue of Unlisted Options for the provision of (If issued as consideration for the corporate advisory services. acquisition of assets, clearly identify those assets) 6a Yes Is the entity an ⁺eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i The date the security holder 6b 29 October 2013 resolution under rule 7.1A was passed 400,000 Adviser Options 6с Number of +securities issued without security holder approval under rule 7.1 6d Number of +securities issued with Nil security holder approval under rule 7.1A 6e Nil Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

⁺ See chapter 19 for defined terms.

| 6f | Number of securities issued under an exception in rule 7.2 | Nil | |
|----|--|---------------------------------|--|
| 6g | If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation. | N/A | |
| 6h | If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements | N/A | |
| 6i | Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements | 7.1 7,022,682 7.1A 5,494,398 | |
| 7 | Dates of entering *securities into uncertificated holdings or despatch of certificates | 11 September 2014 | |
| | | Number | +Class |
| 8 | Number and +class of all +securities quoted on ASX (<i>including</i> the securities in section 2 if applicable) | 44,962,902 | Ordinary Fully Paid Shares (CYP) |
| | 17 | 11,108,500 | Options exercise price \$0.20 expiring 31 December 2014 (CYPO) |

⁺ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (*including* the securities in section 2 if applicable)

| Number | +Class |
|------------|---|
| 10,000,001 | Fully Paid Ordinary Shares (CYPAA) escrowed until 22 November 2014. |
| 500,000 | Unlisted Options exercise price \$0.40, expiring 9 September 2016 (CYPAK) – escrowed until 29 November 2015. |
| 5,000,000 | Unlisted Options exercise price \$0.40, expiring 27 September 2018 (subject to vesting conditions) (CYPAI) – escrowed until 29 November 2015. |
| 200,000 | Unlisted Options exercise price \$0.40, expiring 30 November 2015 (vesting on 29 May 2015). |
| 1,000,000 | Unlisted Options exercise price \$0.40, expiring 30 November 2015 (vesting on 1 December 2014). |

| 10 | Dividend policy (in the case of a |
|----|------------------------------------|
| | trust, distribution policy) on the |
| | increased capital (interests) |

| N/A | | | |
|-----|--|--|--|
| | | | |
| | | | |
| | | | |

Part 2 - Bonus issue or pro rata issue

| 11 | Is security holder approval required? |
|----|--|
| | |
| 12 | Is the issue renounceable or non-renounceable? |
| | |
| 13 | Ratio in which the ⁺ securities will be offered |
| | |
| 14 | ⁺ Class of ⁺ securities to which the offer relates |
| | <u></u> |
| 15 | ⁺ Record date to determine entitlements |
| | <u>'</u> |
| 16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? |

⁺ See chapter 19 for defined terms.

| 17 | Policy for deciding entitlements in relation to fractions | |
|----|---|--|
| | relation to fractions | |
| 18 | Names of countries in which the entity has *security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. | |
| 19 | Closing date for receipt of acceptances or renunciations | |
| 20 | Names of any underwriters | |
| 21 | Amount of any underwriting fee or commission | |
| 22 | Names of any brokers to the issue | |
| 23 | Fee or commission payable to the broker to the issue | |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders | |
| 25 | If the issue is contingent on *security holders' approval, the date of the meeting | |
| 26 | Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled | |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | |
| 28 | Date rights trading will begin (if applicable) | |
| 29 | Date rights trading will end (if applicable) | |

⁺ See chapter 19 for defined terms.

| 30 | How do *security holders sell their entitlements in full through a broker? |
|-----------------|--|
| 31 | How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance? |
| 32 | How do *security holders dispose of their entitlements (except by sale through a broker)? |
| 33 | ⁺ Despatch date |
| | |
| | 3 - Quotation of securities I only complete this section if you are applying for quotation of securities |
| 34 | Type of securities (tick one) |
| (a) | Securities described in Part 1 |
| (b) | All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employe incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities |
| Entiti | es that have ticked box 34(a) |
| Addit | onal securities forming a new class of securities |
| Tick t docun | indicate you are providing the information or ents |
| 35 | If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders |
| 36 | If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over |
| 37 | A copy of any trust deed for the additional *securities |

⁺ See chapter 19 for defined terms.

| Entities that have ticked box 34(b) | | | | |
|-------------------------------------|---|--------|--------|--|
| 38 | Number of securities for which ⁺ quotation is sought | | | |
| 39 | Class of *securities for which quotation is sought | | | |
| 40 | Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities? | | | |
| | If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | | | |
| 41 | Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another | | | |
| | security, clearly identify that other security) | | | |
| 42 | Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the securities in clause 38) | Number | +Class | |
| | | | | |

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Date: 11 September 2014 (Director/Company secretary)

Print name: Peter Webse

== == == ==

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

Part 1

| Rule 7.1 – Issues exceeding 15% of capital | | |
|--|-----------------------|--|
| Step 1: Calculate "A", the base fig capacity is calculated | gure from | which the placement |
| Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue | 31,798,743 | (Adjusted to post consolidation) |
| Add the following: Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid ordinary | 589,042 22,500,001 | Exercise of Options (adjusted to post consolidation) 22 November 2013 |
| securities issued in that 12 month period with shareholder approval Number of partly paid ordinary securities that became fully paid in that 12 month period | 56,201 | Exercise of Options |
| Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items | | |
| Subtract the number of fully paid ordinary securities cancelled during that 12 month period | - | |
| "A" | 54,943,987 | |

⁺ See chapter 19 for defined terms.

| Step 2: Calculate 15% of "A" | | |
|--|---|--|
| "B" | 0.15 [Note: this value cannot be changed] | |
| Multiply "A" by 0.15 | 8,241,598 | 8 |
| Step 3: Calculate "C", the amount 7.1 that has already been used | of place | ement capacity under rule |
| Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued: | 18,916 | Ordinary Fully Paid Shares issued on 2 October 2013 (adjusted to post consolidation) |
| Under an exception in rule 7.2 | 800,000 | Unlisted Options issued on |
| Under rule 7.1A | 400.000 | 29 May 2014 |
| With security holder approval under rule 7.1 or rule 7.4 | 400,000 | Unlisted Options issued on 11 September 2014 (the subject of this Appendix 3B) |
| This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items | | |
| "C" | 1,218,916 | |
| Step 4: Subtract "C" from ["A" x ' placement capacity under rule 7.1 | _ | alculate remaining |
| "A" x 0.15 | 8,241,598 | 8 |
| Note: number must be same as shown in Step 2 | | |
| Subtract "C" | 1,218,910 | 6 |
| Note: number must be same as shown in Step 3 | | |
| Total ["A" x 0.15] – "C" | 7,022,682 | 2 |
| | | is is the remaining placement under rule 7.1] |

⁺ See chapter 19 for defined terms.

Part 2

| Rule 7.1A – Additional placement capacity for eligible entities | | |
|--|-------------------------------|--|
| Step 1: Calculate "A", the base fig | gure from which the placement | |
| "A" Note: number must be same as shown in Step 1 of Part 1 Step 2: Calculate 10% of "A" 54,943,987 | | |
| "D" 0.10 Note: this value cannot be changed | | |
| Multiply "A" by 0.10 5,494,398 | | |
| Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used | | |
| Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items | - | |

⁺ See chapter 19 for defined terms.

| Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A | |
|---|--|
| "A" x 0.10 Note: number must be same as shown in | 5,494,398 |
| Step 2 Subtract "E" Note: number must be same as shown in | - |
| Step 3 Total ["A" x 0.10] – "E" | 5,494,398 |
| | Note: this is the remaining placement capacity under rule 7.1A |

⁺ See chapter 19 for defined terms.